Corryn Biotechnologies Secures Major Investment for US Market Expansion
Advanced skincare and cosmetics company Corryn Biotechnologies has successfully secured a substantial £500,000 equity investment to accelerate the commercialisation and scale-up of its innovative cosmetic aftercare products across both the United Kingdom and United States markets.
Investment Details and Strategic Backing
The significant funding round was spearheaded by the Development Bank of Wales, demonstrating continued confidence in the company's growth trajectory. This investment represents a follow-on commitment from the bank, building upon an earlier investment made in March 2024 that helped advance the company's product development pipeline.
Additional financial support came from the Wales Technology Seed Fund II and the Wales Angel Co‑Investment Fund, alongside a diverse syndicate of eleven business angels from the United Kingdom, United States, and Brazil, plus SFC Capital Partners. This collaborative funding approach highlights the broad investor appeal of Corryn's technology and business model.
Manufacturing Expansion and Job Creation in Wales
Based at the Bay Technology Centre in Port Talbot, Corryn Biotechnologies has established sophisticated clean room manufacturing capabilities alongside advanced fabrication and characterisation laboratories. This infrastructure positions the company to grow high-tech manufacturing within the region while maintaining its Welsh roots despite international expansion plans.
The investment is expected to support the creation of nine new jobs in Wales over the coming years, including two immediate positions and seven additional technically skilled roles as manufacturing operations scale up. This job creation reinforces the company's commitment to developing local talent and economic opportunities in south Wales.
Innovative Technology and Market Opportunity
Corryn's primary technology involves a handheld device that applies a matrix of extremely fine polymer fibres directly onto the skin, maximising therapeutic and aesthetic benefits for various care and beauty applications. These advanced materials create a breathable, porous covering that conforms precisely to skin contours while capable of carrying beneficial additives.
The technology is currently finalising regulatory approvals to permit commercial use as a cosmetic product, initially targeting the UK and US markets with planned expansion to additional territories beginning in 2027. The company is simultaneously strengthening its intellectual property position with two patents pending related to its core technology and manufacturing processes.
Leadership Perspectives on Growth Strategy
Luke Burke, co-founder and chief executive of Corryn Biotechnologies, emphasised the importance of the Development Bank of Wales's early support: "Having the Development Bank of Wales backing us from an early stage has been hugely important in helping us reach this point. This investment gives us the runway to commercialise and scale in the UK and US, while keeping our manufacturing and job creation firmly rooted here in Port Talbot."
Tom Davies, investment executive at the Development Bank of Wales, highlighted the company's strengths: "Corryn is a standout example of a Wales-based business developing real strength in research, product development and manufacturing. Our early-stage investment enabled the team to advance its product pipeline, and this follow-on funding supports the next phase—commercialisation and scale-up."
Adrian de Courcey, lead investor for the business angel syndicate, noted the compelling investment case: "Corryn has developed a compelling product and a clear commercial plan for scaling in the UK and US. The combination of a growing market opportunity, strong execution focus and an established base in Wales made this an attractive investment."
Market Context and Global Ambitions
The funding arrives during a period of strong global demand within the cosmetics and personal care sector, where the aesthetics market represents a multi-billion-dollar industry experiencing significant growth. The company maintains its operational anchor in Wales while developing a strategic presence in the United States, where one of its co-founders is based, facilitating market entry and expansion efforts.
